

David R Martinez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3803842/publications.pdf>

Version: 2024-02-01

39
papers

12,141
citations

147566

31
h-index

276539

41
g-index

55
all docs

55
docs citations

55
times ranked

18658
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. <i>Cell</i> , 2020, 182, 429-446.e14.	13.5	1,257
2	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	13.7	1,153
3	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978
4	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	13.7	956
5	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
6	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
7	The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , 2020, 5, .	5.6	772
8	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
9	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. <i>Nature</i> , 2020, 586, 560-566.	13.7	527
10	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	6.0	459
11	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. <i>Nature Medicine</i> , 2020, 26, 1422-1427.	15.2	450
12	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	2.9	412
13	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347
14	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	283
15	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
16	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
17	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
18	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021, 373, 991-998.	6.0	144

#	ARTICLE	IF	CITATIONS
19	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
20	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. <i>Cell</i> , 2020, 183, 429-441.e16.	13.5	100
21	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
22	Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques. <i>Journal of Virology</i> , 2021, 95, .	1.5	87
23	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29832-29838.	3.3	81
24	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
25	Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. <i>MAbs</i> , 2020, 12, 1778435.	2.6	57
26	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021, 2, 100313.	3.3	56
27	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. <i>Science Translational Medicine</i> , 2022, 14, eabm3410.	5.8	49
28	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	46
29	Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. <i>Cell Reports</i> , 2020, 33, 108226.	2.9	43
30	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	7.0	39
31	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021, 36, 109450.	2.9	38
32	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. <i>MSphere</i> , 2021, 6, e0027521.	1.3	36
33	Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. <i>Cell Host and Microbe</i> , 2020, 27, 710-724.e7.	5.1	25
34	Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. <i>Cell Host and Microbe</i> , 2021, 29, 13-22.	5.1	24
35	Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. <i>PLoS Pathogens</i> , 2020, 16, e1008303.	2.1	18
36	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, e0097421.	1.5	12

#	ARTICLE	IF	CITATIONS
37	A Multitrait Locus Regulates Sarbecovirus Pathogenesis. MBio, 2022, 13, .	1.8	11
38	A potential silver lining of delaying the second dose. Nature Immunology, 2022, 23, 349-351.	7.0	8
39	Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. Journal of Virology, 2022, 96, e0023122.	1.5	2